This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/mesh/concept/
n23http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/kegg-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/pdb/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/mixture/
n25http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/pubchem-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/pubchem-substance/
n13http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB02703/identifier/chebi/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB02703
rdf:type
n3:Drug
n3:description
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.
n3:dosage
n19:271B5079-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Approximately 5 to 6 hours in adults.
n3:indication
For the treatment of bacterial infections.
owl:sameAs
n13:DB02703 n20:DB02703
dcterms:title
Fusidic Acid
adms:identifier
n11:2271900 n14:DB02703 n15:29013 n16:D04281 n17:PA164749648 n18:FUA n21:Fusidic_acid n23:C06694 n24:46505364 n25:3000226
n3:mechanismOfAction
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.
n3:synonym
Fusidate Fusidic acid Fucidin acid Fucidate Fusidine Ramycin
n3:foodInteraction
Take with food to reduce irritation.
n3:mixture
n22:271B5075-363D-11E5-9242-09173F13E4C5 n22:271B5076-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
97 to 99%
n3:salt
n3:synthesisReference
Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Selvaraj Balkrishnan, " PROCESS TO MAKE FUSIDIC ACID CREAM." U.S. Patent US20110301138, issued December 08, 2011.
n8:hasConcept
n9:M0008910
n3:IUPAC-Name
n4:271B507E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5084-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5083-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5080-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5081-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5082-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B507C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B507D-363D-11E5-9242-09173F13E4C5 n4:271B507A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B507B-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B5095-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:D09AA02 n7:S01AA13 n7:J01XC01 n7:D06AX01
n3:H-Bond-Acceptor-Count
n4:271B508A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B508B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5085-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5086-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5088-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5087-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5089-363D-11E5-9242-09173F13E4C5
n3:absorption
Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
6990-06-3
n3:category
n3:containedIn
n5:271B5077-363D-11E5-9242-09173F13E4C5 n5:271B5078-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5090-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5092-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5093-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5094-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B508F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B508E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5091-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B507F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B508C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B508D-363D-11E5-9242-09173F13E4C5